PKD Cures Act
- Sponsor
- Rep. Wasserman Schultz, Debbie [D-FL-25]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jun 4, 2026
Bottom line
The PKD Cures Act aims to accelerate the understanding and treatment of polycystic kidney disease by directing the NIH to expand targeted research and develop a strategic roadmap for future innovation.
What it actually does
This bill, titled the 'PKD Cures Act,' mandates the National Institutes of Health (NIH) to expand and intensify research activities specifically focused on polycystic kidney disease (PKD). It directs the NIH to conduct basic, translational, and clinical research, foster collaborations with various stakeholders, and support training programs for PKD specialists. Additionally, the bill requires the NIH Director to establish a working group to develop a comprehensive roadmap for PKD research and innovation, including identifying gaps, recommending collaboration strategies, and proposing timelines, with a report to Congress within 24 months.
Proponents argue
Proponents argue that this bill addresses a critical public health need by focusing federal research efforts on a devastating genetic disease that affects hundreds of thousands of Americans and costs Medicare billions annually. They contend that dedicated research and a strategic roadmap are essential to developing new treatments, improving patient outcomes, and ultimately reducing the burden of PKD on individuals and the healthcare system.
Opponents contend
While specific opposition to disease-specific research is rare, potential critics might raise concerns about the precedent of mandating research for specific diseases, arguing it could lead to a less flexible and less scientifically driven allocation of NIH resources. They might suggest that such decisions are best left to the discretion of scientific experts within the NIH to ensure funding goes to the most promising research across all health areas.
The bill is very short and clearly written, making it highly accessible for a reader to understand its core provisions quickly.
Section 3, adding Section 434B to the Public Health Service Act
Expansion of NIH Research on Polycystic Kidney Disease
This provision directs the Director of the relevant Institute within NIH (likely the National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK) to significantly increase and focus research efforts on polycystic kidney disease (PKD). This includes foundational research into the disease's genetic and molecular causes, applied research to find markers and potential treatments, and studies to test the safety and effectiveness of new and existing therapies. It also requires the NIH to work with other federal agencies, universities, and private companies, and to train more researchers and doctors specializing in PKD.
Supporters argue
Supporters argue that this expanded research is crucial for advancing scientific understanding and developing life-saving treatments for PKD, a disease with significant morbidity and mortality. They emphasize that a focused effort will accelerate discoveries and bring hope to patients and families.
Critics contend
No specific opposition is typically raised against this provision because it focuses on medical research for a serious disease. However, some might generally argue that congressional mandates for specific disease research could divert resources from other critical areas or limit the NIH's flexibility to pursue the most promising scientific avenues.
Tradeoffs
The primary tradeoff involves balancing targeted disease-specific research with the broader, investigator-initiated research portfolio of the NIH. While focused efforts can accelerate progress in a specific area, they might implicitly reduce resources or attention available for other diseases or fundamental biological questions.
Section 3, adding Section 434C to the Public Health Service Act
Development of Comprehensive PKD Roadmap
This provision requires the Director of NIH to create a special working group. This group will be tasked with developing a detailed plan, or 'roadmap,' for future research and innovation related to polycystic kidney disease. The working group will include experts in kidney disease, genetics, and molecular biology, as well as representatives from patient advocacy groups. Their responsibilities include identifying gaps in current research, suggesting ways for public and private sectors to work together, setting goals and timelines for progress, and figuring out how to use new technologies like artificial intelligence and precision medicine in PKD research. The group must then submit a report with their findings and the roadmap to Congress within two years.